53619R102
Iovance Biotherapeutics Inc
Could not find a ticker for this position, may be a filing error
A California biotech that turns a patient's own tumor-fighting immune cells into a cancer treatment, sold as the drug Amtagvi for advanced melanoma. It started in 2007 as Genesis Biopharma, later merged with Lion Biotechnologies, and took the name Iovance in 2017. Its Amtagvi became the first cell therapy the FDA approved for a solid tumor cancer in 2024.
CUSIP: 53619R102HealthcareUS1 holder